白细胞介素2可预防移植物抗宿主病，同时保留同种异体T细胞的移植物抗白血病效应。
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.
作者信息
Sykes M, Romick M L, Sachs D H
机构信息
Transplantation Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
出版信息
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633-7. doi: 10.1073/pnas.87.15.5633.
Abstract
We have recently demonstrated that interleukin 2 (IL-2), when administered in high doses for several days beginning on the day of allogeneic bone marrow transplantation (BMT), markedly diminishes graft-versus-host disease (GVHD) mortality in lethally irradiated mice. An optimal anti-GVHD effect was attained by coadministering T-cell-depleted (TCD) syngeneic marrow. We demonstrate here that the full graft-versus-leukemia effect of allogeneic T lymphocytes is obtained even when GVHD is markedly diminished by the coadministration of IL-2 and TCD syngeneic marrow. This methodology represents an approach to the treatment of leukemia in which the beneficial effects of allogeneic T cells can be exploited while their major deleterious effect, GVHD, is avoided. These results may thus have an impact on the clinical use of BMT for the treatment of hematologic malignancies.
摘要
我们最近证明，从同种异体骨髓移植（BMT）当天开始连续数天给予高剂量白细胞介素2（IL-2），可显著降低致死性照射小鼠的移植物抗宿主病（GVHD）死亡率。通过同时给予去除T细胞（TCD）的同基因骨髓可获得最佳的抗GVHD效果。我们在此证明，即使通过联合给予IL-2和TCD同基因骨髓显著降低了GVHD，仍可获得同种异体T淋巴细胞的完全移植物抗白血病效应。这种方法代表了一种治疗白血病的途径，即可以利用同种异体T细胞的有益作用，同时避免其主要有害作用GVHD。因此，这些结果可能会对BMT在血液系统恶性肿瘤治疗中的临床应用产生影响。
相似文献
1
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.白细胞介素2可预防移植物抗宿主病，同时保留同种异体T细胞的移植物抗白血病效应。
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633-7. doi: 10.1073/pnas.87.15.5633.
2
Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.使用混合异基因骨髓移植的移植物抗白血病效应
Bone Marrow Transplant. 1989 Sep;4(5):465-74.
3
IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.白细胞介素-11可在骨髓移植后将移植物抗白血病效应与移植物抗宿主病区分开来。
J Clin Invest. 1999 Aug;104(3):317-25. doi: 10.1172/JCI7111.
4
5
Alloengraftment in IL-2-treated mice.在接受白细胞介素-2治疗的小鼠中的异基因移植。
Bone Marrow Transplant. 1992 Aug;10(2):157-63.
6
Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.在B细胞白血病/淋巴瘤小鼠模型中，T细胞去除的异基因骨髓移植后，不依赖移植物抗宿主病的有效移植物抗白血病效应。细胞疗法和重组白细胞介素-2的作用
J Immunol. 1994 Sep 15;153(6):2562-7.
7
IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.白细胞介素-2可抑制与移植物抗宿主病相关的血清γ干扰素水平的早期升高。
Transplantation. 1994 Dec 27;58(12):1385-93.
8
Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.用于根除微小残留病的异基因细胞介导免疫疗法：小鼠模型中T细胞和白细胞介素-2激活的杀伤细胞（LAK细胞）介导的过继性免疫疗法的比较
Exp Hematol. 1999 Mar;27(3):461-9. doi: 10.1016/s0301-472x(98)00026-5.
9
Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.非T细胞去除的同种异体骨髓移植受者中的抑制活性：T细胞去除的同基因骨髓的作用。
Bone Marrow Transplant. 1989 Dec;4 Suppl 4:30-3.
10
In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.体内给予白细胞介素2加去除T细胞的同基因骨髓可预防移植物抗宿主病死亡并允许同种异体移植。
J Exp Med. 1990 Mar 1;171(3):645-58. doi: 10.1084/jem.171.3.645.
引用本文的文献
1
The impact of regulatory T cells on the graft-versus-leukemia effect.调节性 T 细胞对移植物抗白血病效应的影响。
Front Immunol. 2024 Apr 22;15:1339318. doi: 10.3389/fimmu.2024.1339318. eCollection 2024.
2
Treg-targeted IL-2/anti-IL-2 complex controls graft--host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation.Treg 靶向的 IL-2/抗 IL-2 复合物控制移植物抗宿主病，并在异基因造血干细胞移植中支持抗肿瘤作用。
Haematologica. 2024 Jan 1;109(1):129-142. doi: 10.3324/haematol.2022.282653.
3
T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?辅助性 T 细胞谱系定义转录因子：特异性移植物抗宿主病治疗的有效靶点？
Front Immunol. 2022 Jan 5;12:806529. doi: 10.3389/fimmu.2021.806529. eCollection 2021.
4
Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges.调节性 T 细胞治疗移植物抗宿主病：进展与挑战。
Int J Mol Sci. 2021 Sep 7;22(18):9676. doi: 10.3390/ijms22189676.
5
Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease.用于治疗移植物抗宿主病的免疫调节疗法。
Hemasphere. 2021 Jun 1;5(6):e581. doi: 10.1097/HS9.0000000000000581. eCollection 2021 Jun.
6
Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.耐受性抗白细胞介素-2单克隆抗体可预防移植物抗宿主病，同时保留强大的移植物抗白血病活性。
Blood. 2021 Apr 22;137(16):2243-2255. doi: 10.1182/blood.2020006345.
7
Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.针对 CD45RC 的瞬时抗体抑制移植物抗宿主病的发展。
Blood Adv. 2020 Jun 9;4(11):2501-2515. doi: 10.1182/bloodadvances.2020001688.
8
HLA-Class II Artificial Antigen Presenting Cells in CD4 T Cell-Based Immunotherapy.HLA-II 类人工抗原呈递细胞在基于 CD4 T 细胞的免疫治疗中的应用。
Front Immunol. 2019 May 17;10:1081. doi: 10.3389/fimmu.2019.01081. eCollection 2019.
9
Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.低剂量白细胞介素-2作为造血干细胞移植后调节性T细胞稳态的调节剂：当前认识与未来展望
Int J Hematol. 2018 Feb;107(2):130-137. doi: 10.1007/s12185-017-2386-y. Epub 2017 Dec 12.
10
Targeting Cytokines in GVHD Therapy.移植物抗宿主病治疗中细胞因子的靶向治疗
J Immunol Res Ther. 2017;2(1):90-99. Epub 2017 Jun 28.
本文引用的文献
1
Studies in antibody response of mice to tumour inoculation.小鼠对肿瘤接种的抗体反应研究。
Br J Cancer. 1950 Dec;4(4):372-9. doi: 10.1038/bjc.1950.36.
2
Monoclonal antibodies to mouse major histocompatibility complex antigens.针对小鼠主要组织相容性复合体抗原的单克隆抗体。
Transplantation. 1982 Sep;34(3):113-20. doi: 10.1097/00007890-198209000-00001.
3
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation.慢性移植物抗宿主病的抗白血病效应：对异基因骨髓移植后生存率提高的贡献。
N Engl J Med. 1981 Jun 18;304(25):1529-33. doi: 10.1056/NEJM198106183042507.
4
Systemic administration of recombinant human interleukin-2 in mice.重组人白细胞介素-2在小鼠体内的全身给药。
J Biol Response Mod. 1984 Oct;3(5):561-72.
5
Monoclonal anti-H-2Kb antibodies detect serological differences between H-2Kb mutants.单克隆抗H-2Kb抗体可检测出H-2Kb突变体之间的血清学差异。
Immunogenetics. 1981;12(1-2):183-6. doi: 10.1007/BF01561661.
6
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.通过全身给予高剂量重组白细胞介素2介导已建立的肺转移瘤和皮下肿瘤的消退。
J Exp Med. 1985 May 1;161(5):1169-88. doi: 10.1084/jem.161.5.1169.
7
8
Histoincompatible bone marrow transplants in humans.人类中的组织不相容性骨髓移植。
Annu Rev Immunol. 1987;5:43-64. doi: 10.1146/annurev.iy.05.040187.000355.
9
10
Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2.输注白细胞介素-2治疗难治性或复发性B细胞慢性淋巴细胞白血病患者肿瘤缩小的证据。
Nouv Rev Fr Hematol (1978). 1988;30(5-6):475-8.
Zotero 插件